Bryan Goodwin
Senior Vice President, Head of Biology and Translational Sciences
Professional Overview
Bryan Goodwin is a seasoned biopharmaceutical executive with over 20 years of experience in leading drug discovery and translational research programs across diverse therapeutic areas. As the Senior Vice President and Head of Biology and Translational Sciences at Morphic Therapeutic, he oversees the company's integrated biology and translational sciences functions, spearheading the development of innovative therapeutics targeting complex diseases.
Experience Summary
Current Role
As the Senior Vice President and Head of Biology and Translational Sciences at Morphic Therapeutic, Bryan is responsible for driving the company's drug discovery and development programs. He leads a talented team of scientists in advancing the company's pipeline of integrin-targeted therapeutics, with a focus on areas such as fibrosis, inflammation, and immuno-oncology. Under his leadership, Morphic has made significant progress in bringing novel drug candidates into the clinic, demonstrating the company's commitment to delivering transformative treatments to patients.
Career Progression
Prior to joining Morphic, Bryan held several senior research leadership roles, including Vice President, Head of Biology at Enanta Pharmaceuticals, Senior Director, Head of Gastrointestinal, Metabolic, and Endocrine Research Therapeutic Area at Shire, and Senior Director, Muscle Metabolism, Cardiovascular and Metabolic Disease Research Unit at Pfizer. He has a proven track record of successfully advancing drug candidates from the discovery stage through clinical development, with several compounds reaching regulatory approval. Throughout his career, Bryan has made substantial contributions to the advancement of novel therapeutic modalities and has been instrumental in driving the industry's efforts to address unmet medical needs.
Academic Background
Bryan holds a Ph.D. in Biochemistry from the University of California, San Diego, where he specialized in the study of cellular signaling pathways and protein-protein interactions. His academic achievements include several peer-reviewed publications and presentations at prestigious scientific conferences.
Areas of Expertise
- Drug discovery and translational research
- Integrin biology and targeting
- Fibrosis, inflammation, and immuno-oncology
- Translational biomarkers and pharmacodynamic assays
- Cross-functional team leadership and collaboration
- Strategic planning and portfolio management
Professional Impact
During his tenure at Morphic, Bryan has played a pivotal role in advancing the company's lead integrin-targeted drug candidates into clinical development, including the successful completion of multiple Phase 1 and Phase 2 trials. His expertise in translational research has been instrumental in guiding the company's efforts to identify and validate biomarkers that can help predict and monitor patient response to treatment. Additionally, Bryan has been actively engaged in industry collaborations and scientific advisory board roles, contributing to the broader scientific community's understanding of integrin biology and its therapeutic applications.
Conclusion
With his extensive experience in drug discovery and translational research, coupled with his strong leadership skills and collaborative approach, Bryan Goodwin is well-positioned to drive Morphic Therapeutic's continued growth and success in the development of innovative integrin-targeted therapeutics. His deep industry knowledge and proven track record of delivering tangible results make him a valuable asset to the company and the broader biopharmaceutical community.
